Single-cell Analysis Global Market Report 2024

Single-cell analysis involves the study of transcriptomics, genomics, proteomics, cell interactions, and metabolomics at the individual cell level. This field aids in standardizing and automating workflows to gather information crucial for treating various diseases, including cancer. Activities in single-cell analysis revolve around research and experimental development in this specialized area.

The primary categories of single-cell analysis include consumables and instruments. Consumables are employed in tasks such as exosome analysis, genetic exploration, and isolation of RNA and DNA. The workflow of single-cell analysis comprises single-cell isolation and library preparation, downstream analysis, and data analysis. Techniques utilized in this process encompass flow cytometry, next-generation sequencing, polymerase chain reaction (PCR), microscopy, mass spectrometry, among others. Single-cell analysis finds applications in diverse areas such as cancer research, immunology, neurology, stem cell studies, non-invasive prenatal diagnosis, in-vitro fertilization, and more. The end-users of single-cell analysis include academic and research laboratories, biotechnology and pharmaceutical companies, as well as hospital and diagnostic laboratories.

The single-cell analysis market research report is one of a series of new reports that provides single-cell analysis market statistics, including single-cell analysis industry global market size, regional shares, competitors with a single-cell analysis market share, detailed single-cell analysis market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell analysis industry. This single-cell analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single-cell analysis market size has grown rapidly in recent years. It will grow from $3.14 billion in 2023 to $3.53 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed in the historic period can be attributed to factors such as a surge in research activities in genomics, increased funding in the field, and advancements in biopharmaceutical research and development (R&D).

The single-cell analysis market size is expected to see rapid growth in the next few years. It will grow to $6.02 billion in 2028 at a compound annual growth rate (CAGR) of 14.3%. The anticipated growth in the forecast period can be attributed to a broader application scope, increased adoption in clinical diagnostics, and advancements in data analysis techniques. Key trends expected in this period include increased collaborations and partnerships, integration of multi-omics approaches, advancements in single-cell spatial analysis, automation and high-throughput technologies, as well as the integration of artificial intelligence (AI) and machine learning. Additionally, the expanding applications of single-cell analysis in neurology are expected to contribute to the overall growth in this field.

The increasing emphasis on personalized medicine globally is playing a significant role in fostering the expansion of the single-cell analysis market. Personalized medicine involves leveraging an individual's genetic profile to make informed decisions about disease treatment, prevention, and diagnosis. Single-cell analysis contributes valuable insights into the specific needs of individual patients, the nature of diseases, and tailoring personalized treatment approaches. This shift towards personalized medicine is evident in patient preferences, as indicated by a July 2021 survey by Dosis, a dosing platform provider. The survey of 1,000 participants revealed that 85% of patients believe personalized medicine will enhance their care, and 80% feel that it should be accessible to all. Thus, the growing focus on personalized medicine is a key driver behind the market's growth.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the single-cell analysis market in the foreseeable future. Chronic diseases, characterized by prolonged durations and lack of preventative or vaccination-based treatment, benefit from the insights provided by single-cell analysis. This approach enables a deeper understanding of the pathophysiology of chronic illnesses, paving the way for more tailored and effective treatment options. For instance, as of March 2022, the Australian Bureau of Statistics reported that over three-quarters of Australians (78.6%) had at least one long-term health problem, with nearly half (46.6% or 11.6 million) dealing with at least one chronic ailment. Thus, the increasing prevalence of chronic diseases is a driving force behind the growth of the single-cell analysis market.

Companies operating in the single-cell analysis market are concentrating on technological advancements to ensure the intact and viable preservation of single cells. Technological innovations are being leveraged to maintain sample integrity during shipping, storage, and processing, leading to higher recovery rates of delicate cells and eliminating the need for specialized instruments. For example, in October 2021, PerkinElmer and Honeycomb Biotechnologies introduced the HIVE scRNAseq solution, a portable, single-use handheld device facilitating gentle capture, robust storage, and easy processing for the analysis of single-cell samples. This system caters to various cell types, including fragile ones like granulocytes, nephrons, hepatocytes, and neurons, offering simplicity and potential benefits for laboratories engaged in diverse research domains.

Major players in the single-cell analysis market are committed to developing innovative products to better serve their existing consumer base. In December 2022, Scale Biosciences Inc. launched ScaleBio’s scRNAseq solution, utilizing the company's proprietary combinatorial indexing technology. This solution allows for the scanning of up to 96 samples and thousands of cells in a single study, at a cost significantly lower than existing single-cell systems. The scRNAseq solution is designed for the characterization of cell lines, PBMCs, and nuclei, providing a fixation kit for sample fixation, storage, and transport.

In August 2021, Danaher Corporation acquired Aldevron LLC, strengthening its capabilities in the vital field of genomic medicine. This strategic move supports Danaher Corporation's objective of expediting the delivery of life-saving treatments and vaccines to the market. Aldevron LLC is a manufacturing company specializing in gene and cell therapies.

Major companies operating in the in the single-cell analysis market report are Becton Dickinson and Company, Merck KGAA, QIAGEN N. V., Thermo Fisher Scientific Inc., Illumina Inc., Standard BioTools Inc., 10X Genomics Inc., Bio-Rad Laboratories Inc., Novogene Corporation Limited, Agilent Technologies Inc., Sartorius AG, Luminex Corporation, Fluxion Biosciences Inc., Oxford Nanopore Technologies Ltd., 1CellBio Inc., 3D Biomatrix Inc., ACEA Biosciences Inc., Akoya Biosciences Inc., Berkeley Lights Inc., Bio-Techne Corporation, Celsee Inc., Cellular Research Inc., Cytena GmbH, Dolomite Bio Limited, Drop-seq Technologies Inc., Epic Sciences Inc., Ginkgo Bioworks Inc., IsoPlexis Corporation, Menarini Silicon Biosystems S. p. A., Mission Bio Inc., NanoCellect Biomedical Inc., NemaMetrix Inc., OnRamp Bioinformatics Inc., Partek Incorporated, RareCyte Inc., Scienion AG, SeqWell Inc., Sphere Fluidics Limited, Takara Bio USA Holdings Inc.

North America was the largest region in the single-cell analysis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the single-cell analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The single-cell analysis market includes revenues earned by entities by providing services such as antibody-based methods, fluorescent protein-based methods, and mass-spectroscopy based methods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.